Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne
To review the efficacy and safety of clascoterone 1% cream for the treatment of acne vulgaris in patients 12 years of age and older. A literature search through PubMed, MEDLINE, and ClinicalTrials.gov was conducted using the following keywords: , , , and . Articles published between 2004 and 2020 we...
Saved in:
Published in | The Annals of pharmacotherapy p. 1060028021992053 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.10.2021
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | To review the efficacy and safety of clascoterone 1% cream for the treatment of acne vulgaris in patients 12 years of age and older.
A literature search through PubMed, MEDLINE, and ClinicalTrials.gov was conducted using the following keywords:
,
,
, and
. Articles published between 2004 and 2020 were included in this review.
Preclinical and clinical studies describing the efficacy and safety of topical clascoterone cream were included.
Early preclinical studies demonstrated that clascoterone exhibits local antiandrogenic effects without any systemic effects. Phase 2 and 3 trials demonstrated a statistically significant reduction in inflammatory and noninflammatory lesions and mild erythema with clascoterone use. Long-term studies confirmed the favorable safety profile of the drug in subjects for up to 9 months of use, with erythema being the most common treatment-emergent local skin reaction.
Pharmacological treatment options for acne vulgaris include topical and systemic agents. Systemic antiandrogen medications are associated with adverse effects and should be avoided in pregnancy and male patients. Clascoterone is a novel topical antiandrogen drug with no systemic adverse effects. This drug provides prescribers with an appealing treatment option for male and female patients 12 years of age and older, who are not candidates for systemic drugs because of contraindications or adverse effects or who have failed other topical therapies.
Clascoterone, a novel topical androgen receptor inhibitor, is a safe and effective treatment option for patients with acne vulgaris. |
---|---|
AbstractList | To review the efficacy and safety of clascoterone 1% cream for the treatment of acne vulgaris in patients 12 years of age and older.
A literature search through PubMed, MEDLINE, and ClinicalTrials.gov was conducted using the following keywords:
,
,
, and
. Articles published between 2004 and 2020 were included in this review.
Preclinical and clinical studies describing the efficacy and safety of topical clascoterone cream were included.
Early preclinical studies demonstrated that clascoterone exhibits local antiandrogenic effects without any systemic effects. Phase 2 and 3 trials demonstrated a statistically significant reduction in inflammatory and noninflammatory lesions and mild erythema with clascoterone use. Long-term studies confirmed the favorable safety profile of the drug in subjects for up to 9 months of use, with erythema being the most common treatment-emergent local skin reaction.
Pharmacological treatment options for acne vulgaris include topical and systemic agents. Systemic antiandrogen medications are associated with adverse effects and should be avoided in pregnancy and male patients. Clascoterone is a novel topical antiandrogen drug with no systemic adverse effects. This drug provides prescribers with an appealing treatment option for male and female patients 12 years of age and older, who are not candidates for systemic drugs because of contraindications or adverse effects or who have failed other topical therapies.
Clascoterone, a novel topical androgen receptor inhibitor, is a safe and effective treatment option for patients with acne vulgaris. |
Author | Slugocki, Malgorzata Kalabalik-Hoganson, Julie Ozdener-Poyraz, Ayse Elif Frey, Kathleen M |
Author_xml | – sequence: 1 givenname: Julie orcidid: 0000-0003-0158-3490 surname: Kalabalik-Hoganson fullname: Kalabalik-Hoganson, Julie organization: Fairleigh Dickinson University School of Pharmacy and Health Sciences, Florham Park, NJ, USA – sequence: 2 givenname: Kathleen M surname: Frey fullname: Frey, Kathleen M organization: Fairleigh Dickinson University School of Pharmacy and Health Sciences, Florham Park, NJ, USA – sequence: 3 givenname: Ayse Elif surname: Ozdener-Poyraz fullname: Ozdener-Poyraz, Ayse Elif organization: Fairleigh Dickinson University School of Pharmacy and Health Sciences, Florham Park, NJ, USA – sequence: 4 givenname: Malgorzata surname: Slugocki fullname: Slugocki, Malgorzata organization: Fairleigh Dickinson University School of Pharmacy and Health Sciences, Florham Park, NJ, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33533262$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j0tLxDAURoMozkP3riR_oHpz06aNu1J8DAwKWtdDmtw4lTYpbRX8946oi49zVge-FTsOMRBjFwKuhMjzawEKAAtAoTVCJo_YUmQpJgpzWLDVNL0DgBaoT9lCykxKVLhkL1VnJhtnGg-1G17yx_hJHa_j0FrT8TK4Mb5R4M9kaZjjyDdh3zbtj_nD5j3xeiQz9xRmHj0vbaAzduJNN9H5H9fs9e62rh6S7dP9piq3iZUynxPhKTdUuFRk4JxD1NoZoWUBRonUGq1UCgagcAVR41LfQJNq9EJb0-QZ4ppd_naHj6YntxvGtjfj1-7_HX4DSlpRNQ |
CitedBy_id | crossref_primary_10_1016_j_det_2021_12_004 crossref_primary_10_1177_1060028021992055 crossref_primary_10_1007_s13555_022_00854_3 crossref_primary_10_1007_s40267_022_00941_7 crossref_primary_10_1038_s41598_024_51392_1 |
ContentType | Journal Article |
DBID | NPM |
DOI | 10.1177/1060028021992053 |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1542-6270 |
ExternalDocumentID | 33533262 |
Genre | Journal Article |
GroupedDBID | --- -MK 01A 0R~ 1CY 23M 39C 4.4 54M 5GY 5RE 6J9 6PF AACMV AACTG AADTT AAEWN AAGMC AAJPV AAKGS AAMGE AANSI AARDL AATAA AATBZ AAUAS AAWTL ABAWP ABCCA ABJIS ABJNI ABLUO ABOCM ABPNF ABQXT ABVFX ACARO ACDXX ACFEJ ACGFO ACGFS ACGZU ACJTF ACLFY ACLZU ACOXC ACROE ACSIQ ACTQU ACUAV ACUIR ACXKE ACXMB ADBBV ADGDL ADRRZ AECGH AEDTQ AEKYL AENEX AEPTA AERKM AESZF AEUHG AEUIJ AEWDL AEWHI AFKRG AFMOU AFQAA AGKLV AGWFA AIIQI AIOMO AJUZI AJXAJ ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV AUTPY AUVAJ AYAKG BBRGL BDDNI BKIIM BKSCU BPACV BSEHC BWJAD CS3 DB0 DC. DF0 DO- DV7 EBS EMOBN F5P FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION HZ~ J5H J8X JCYGO K.F L7B LSO M4V NPM O9- P.B P2P Q1R ROL S01 SCNPE SFC SHG SJN SPQ SPV THW WH7 |
ID | FETCH-LOGICAL-c337t-1fe7ae8d4150ddd2299da19380a614ca96640a008d8eebd4fb0b492f19cab7522 |
IngestDate | Thu May 23 23:40:33 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | androgen topical clascoterone acne |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c337t-1fe7ae8d4150ddd2299da19380a614ca96640a008d8eebd4fb0b492f19cab7522 |
ORCID | 0000-0003-0158-3490 |
PMID | 33533262 |
ParticipantIDs | pubmed_primary_33533262 |
PublicationCentury | 2000 |
PublicationDate | 2021-10-01 |
PublicationDateYYYYMMDD | 2021-10-01 |
PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Annals of pharmacotherapy |
PublicationTitleAlternate | Ann Pharmacother |
PublicationYear | 2021 |
SSID | ssj0009129 |
Score | 2.4027455 |
SecondaryResourceType | review_article |
Snippet | To review the efficacy and safety of clascoterone 1% cream for the treatment of acne vulgaris in patients 12 years of age and older.
A literature search... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1060028021992053 |
Title | Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33533262 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2IKFeEG8oD_mAeqGGxM7mwW2FqFYglpVIpd4qO3aWFWUTbbeVdn8FP5nPcZy0C1TAJYriJIpmvoy_Gc-MCXkZxCYUmJkZD4VmUcJTJnVsGMhxpuLCJMnQFgp_msTjo-jD8fB4MPhxKWvpfKVeF5vf1pX8j1ZxDXq1VbL_oNnupbiAc-gXR2gYx7_Ssd3RsqggmWrRlphPqgtz-iqvaid7240AT1tyaGp41zAHX-dqbs98emHeZZpbTlosrqQGNVs2dy2W67bN9epqJ4KPEkgCnf_GxtVM-mIyW3jdgeZw6SLjPnejj8F-3mjb-JpNq_VSNsHs0frM2Gyzsg_fns9gteeutOh0Vi03rqCuC1fwsEt8w2zTmtiIs5i77UJaswm_tFnj5TYZNnDdg3-17c3q8nW3QtL190bXQoDGcmfnrx_d6rbth3bITpJaizmx0R_fxBnkqF_qfrP9Kbvkln98y0lpyEp-h9xuvQw6cpC5SwZmcY_sT53-1gc076vuzg7oPp32DczX98mXy7h6S0e0QRVtUUU9qqhHFe1QRYEqCnjQDlW0KqlF1QNydPg-fzdm7eYbrBAiWbGwNIk0qQbBC7TWHLRFS7D9NJBgdIWEmxwFEgxSp8YoHZUqUFHGyzArpErA6h-SGwt85WNCVRSWmgthsqHAfAEfO1TDRGZwVpStFHtCHjlhndSuw8qJF-PeH0eekt0eXc_IzRJ_gnkOfrhSLxql_QREqWIM |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clascoterone%3A+A+Novel+Topical+Androgen+Receptor+Inhibitor+for+the+Treatment+of+Acne&rft.jtitle=The+Annals+of+pharmacotherapy&rft.au=Kalabalik-Hoganson%2C+Julie&rft.au=Frey%2C+Kathleen+M&rft.au=Ozdener-Poyraz%2C+Ayse+Elif&rft.au=Slugocki%2C+Malgorzata&rft.date=2021-10-01&rft.eissn=1542-6270&rft.spage=1060028021992053&rft_id=info:doi/10.1177%2F1060028021992053&rft_id=info%3Apmid%2F33533262&rft_id=info%3Apmid%2F33533262&rft.externalDocID=33533262 |